Biosimilar Monoclonal Antibody Market (By Type: Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others; By Indication: Oncology, Autoimmune diseases, Others; By End User: Hospitals, Cancer treatment centers, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Biosimilar Monoclonal Antibody Market 

5.1. COVID-19 Landscape: Biosimilar Monoclonal Antibody Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Biosimilar Monoclonal Antibody Market, By Type

8.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Type, 2023-2032

8.1.1 Adalimumab

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. Bevacizumab

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. Infliximab

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. Rituximab

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. Trastuzumab

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Biosimilar Monoclonal Antibody Market, By Indication

9.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by Indication, 2023-2032

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Autoimmune diseases

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

9.1.3. Others

9.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Biosimilar Monoclonal Antibody Market, By End User 

10.1. Biosimilar Monoclonal Antibody Market Revenue and Volume, by End User, 2023-2032

10.1.1. Hospitals

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Cancer treatment centers

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Biosimilar Monoclonal Antibody Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.1.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.2.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.3.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.6.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.4.7.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.4.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Volume Forecast, by End User (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2020-2032)

11.5.5.2. Market Revenue and Volume Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Volume Forecast, by End User (2020-2032)

Chapter 12. Company Profiles

12.1. Roche

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Pfizer

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Samsung Bioepis

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Amgen

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Mylan

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Teva Pharmaceutical Industries

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Biogen

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Celltrion

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Fresenius Kabi

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

PROCEED TO BUY :

   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample